Cargando…
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
BACKGROUND: The clinical benefit of immunotherapeutic approaches against cancer has been well established although complete responses are only observed in a minority of patients. Combination immunotherapy offers an attractive avenue to develop more effective cancer therapies by improving the efficac...
Autores principales: | Beyrend, Guillaume, van der Gracht, Esmé, Yilmaz, Ayse, van Duikeren, Suzanne, Camps, Marcel, Höllt, Thomas, Vilanova, Anna, van Unen, Vincent, Koning, Frits, de Miranda, Noel F. C. C., Arens, Ramon, Ossendorp, Ferry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694641/ https://www.ncbi.nlm.nih.gov/pubmed/31412943 http://dx.doi.org/10.1186/s40425-019-0700-3 |
Ejemplares similares
-
Cytofast: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations
por: Beyrend, Guillaume, et al.
Publicado: (2018) -
Memory CD8(+) T cell heterogeneity is primarily driven by pathogen-specific cues and additionally shaped by the tissue environment
por: van der Gracht, Esmé T.I., et al.
Publicado: (2020) -
A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control
por: Tondini, Elena, et al.
Publicado: (2019) -
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
por: van der Sluis, Tetje C., et al.
Publicado: (2023) -
The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose
por: Redeker, Anke, et al.
Publicado: (2018)